View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
January 20, 2022

Hutchmed commences Phase I trial of solid tumours therapy in China

HMPL-653 has been designed to act on malignant driven tumours as a single agent or in combination with other drugs.

Hutchmed has started a Phase I clinical trial to evaluate its investigational therapy, HMPL-653, for the treatment of patients with advanced malignant solid tumours and tenosynovial giant cell tumours (TGCT), in China.

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

The open-label, single-arm, multi-centre trial will assess the safety, pharmacokinetics, tolerability and preliminary efficacy of the new potent colony-stimulating factor 1 receptor (CSF-1R) inhibitor HMPL-653.

The dose escalation and expansion phase of the study is expected to recruit nearly 110 patients.

Dose limiting toxicity, tolerability, safety, recommended dose for the Phase II study and maximum tolerated dose are the primary goals of the study.

For this Phase I trial, pharmacokinetics, progression free survival, objective response rate are the secondary endpoints.

Other secondary goals include disease control rate and overall survival.

Jilin Cancer Hospital is serving as the lead institution for the study.

Hutchmed retains all rights to HMPL-653 across the globe at present. The therapy has been designed to act on malignant driven tumours as a single agent or along with other drugs.

Expressed usually on macrophages’ surface, CSF-1R attaches with its ligand CSF-1 and can promote growth and differentiation of macrophages.

Several studies have revealed that the tumour microenvironment could be modulated by blocking the CSF-1R signaling pathway. At present, no CSF-1R inhibitor has secured approval in China.

A rare type of soft tissue tumour, TGCT is caused due to abnormal proliferation and inflammation of giant cells, inflammatory cells and monocytes.

In July last year, Hutchmed initiated a Phase I trial of its investigational oral drug, HMPL‑295, to treat advanced malignant solid tumour patients.

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU